OBJECTIVE: Our previous studies demonstrated that simvastatin promotes neurological functional recovery after traumatic brain injury (TBI) in rat; however, the underlying mechanisms remain poorly understood. The purpose of this study was to investigate the anti-inflammatory effect of simvastatin by measuring the level of cytokines and activation of glial cells. METHODS: Controlled cortical impact injury was performed in adult male Wistar rats. The rats were randomly divided into 3 groups: sham, saline control group, and simvastatin treatment group. Simvastatin was administered orally starting at day 1 after TBI until animals were killed at days 1, 3, 7, 14, and 35 after treatment. Functional outcome was measured using modified neurological severity scores. Enzyme-linked immunosorbent assay and immunohistochemical staining were used to measure the expression of interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha and to identify activated microglial cells and astrocytes. RESULTS: At days 1 and 3 after simvastatin or saline treatment, cytokine levels in the lesion boundary zone were significantly higher in the simvastatin- and saline-treated rats compared with the sham group, peaking at day 3. Simvastatin only reduced the level of IL-1beta but not IL-6 and tumor necrosis factor-alpha, compared with the saline group. Also, simvastatin significantly reduced the number of activated microglial cells and astrocytes compared with the saline control animals. There was also a trend toward improvement of modified neurological severity score, reaching statistical significance (P = 0.003) toward the end of the trial. CONCLUSION: Our data demonstrate that TBI causes inflammatory reaction, including increased levels of IL-1beta, IL-6, and tumor necrosis factor-alpha, as well as activated microglial cells. Simvastatin selectively reduces IL-1beta expression and inhibits the activation of microglial cells and astrocytes after TBI, which might be one of the mechanisms underlying the therapeutic benefits of simvastatin treatment of TBI.
OBJECTIVE: Our previous studies demonstrated that simvastatin promotes neurological functional recovery after traumatic brain injury (TBI) in rat; however, the underlying mechanisms remain poorly understood. The purpose of this study was to investigate the anti-inflammatory effect of simvastatin by measuring the level of cytokines and activation of glial cells. METHODS: Controlled cortical impact injury was performed in adult male Wistar rats. The rats were randomly divided into 3 groups: sham, saline control group, and simvastatin treatment group. Simvastatin was administered orally starting at day 1 after TBI until animals were killed at days 1, 3, 7, 14, and 35 after treatment. Functional outcome was measured using modified neurological severity scores. Enzyme-linked immunosorbent assay and immunohistochemical staining were used to measure the expression of interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha and to identify activated microglial cells and astrocytes. RESULTS: At days 1 and 3 after simvastatin or saline treatment, cytokine levels in the lesion boundary zone were significantly higher in the simvastatin- and saline-treated rats compared with the sham group, peaking at day 3. Simvastatin only reduced the level of IL-1beta but not IL-6 and tumor necrosis factor-alpha, compared with the saline group. Also, simvastatin significantly reduced the number of activated microglial cells and astrocytes compared with the saline control animals. There was also a trend toward improvement of modified neurological severity score, reaching statistical significance (P = 0.003) toward the end of the trial. CONCLUSION: Our data demonstrate that TBI causes inflammatory reaction, including increased levels of IL-1beta, IL-6, and tumor necrosis factor-alpha, as well as activated microglial cells. Simvastatin selectively reduces IL-1beta expression and inhibits the activation of microglial cells and astrocytes after TBI, which might be one of the mechanisms underlying the therapeutic benefits of simvastatin treatment of TBI.
Authors: P F Stahel; E Shohami; F M Younis; K Kariya; V I Otto; P M Lenzlinger; M B Grosjean; H P Eugster; O Trentz; T Kossmann; M C Morganti-Kossmann Journal: J Cereb Blood Flow Metab Date: 2000-02 Impact factor: 6.200
Authors: Gennadij Raivich; Marion Bohatschek; Alexander Werner; Leonard L Jones; Matthias Galiano; Christian U A Kloss; Xing-Zu Zhu; Klaus Pfeffer; Zhi Qiang Liu Journal: J Neurosci Res Date: 2003-06-15 Impact factor: 4.164
Authors: Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane Journal: J Neurotrauma Date: 2014-01-20 Impact factor: 5.269
Authors: Susan Margulies; Gail Anderson; Fahim Atif; Jerome Badaut; Robert Clark; Philip Empey; Maria Guseva; Michael Hoane; Jimmy Huh; Jim Pauly; Ramesh Raghupathi; Stephen Scheff; Donald Stein; Huiling Tang; Mona Hicks Journal: J Neurotrauma Date: 2015-08-06 Impact factor: 5.269
Authors: Madhuvanthi A Kandadai; Jason Meunier; Christopher J Lindsell; George J Shaw; Mitchell S V Elkind Journal: Curr Neurovasc Res Date: 2012-08 Impact factor: 1.990
Authors: Krista M Rodgers; Yuetiva K Deming; Florencia M Bercum; Serhiy Y Chumachenko; Julie L Wieseler; Kirk W Johnson; Linda R Watkins; Daniel S Barth Journal: J Neurotrauma Date: 2013-11-20 Impact factor: 5.269
Authors: Eric E Abrahamson; Lesley M Foley; Steven T Dekosky; T Kevin Hitchens; Chien Ho; Patrick M Kochanek; Milos D Ikonomovic Journal: J Cereb Blood Flow Metab Date: 2013-02-27 Impact factor: 6.200